시장보고서

상품코드

1652019

세계의 백신 보조제 시장 : 시장 규모, 점유율, 동향, 업계 분석(제품 종류별, 투여 경로별, 질환 종류별, 용도별, 지역별), 예측(2025-2034년)

Vaccine Adjuvants Market Size, Share, Trends, Industry Analysis Report: By Product Type, Route of Administration, Disease Type, Application, and Region - Market Forecast, 2025-2034

발행일: 2025년 01월 | 리서치사:

Polaris Market Research | 페이지 정보: 영문 119 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 세계 백신 보조제 시장 규모는 2034년까지 60억 3,504만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

백신 보조제 시장에는 면역 반응을 향상시키기 위해 백신에 첨가되는 물질이 포함됩니다. 이러한 보조제는 특히 도전적인 질병에 대한 백신의 효능을 향상시킵니다. 백신 수요 증가, 보조제 기술 발전, 예방접종에 대한 인식 증가가 시장 성장의 원동력이 되고 있습니다. 주요 기업들은 안전성과 효능을 개선한 새로운 보조제 개발에 주력하고 있습니다. 백신 접종 프로그램의 증가와 COVID-19를 비롯한 신흥 질병에 대한 백신의 필요성이 시장을 견인하고 있습니다.

백신 보조제 시장의 성장은 특히 감염성 질환 및 암 면역요법에 대한 효과적인 백신에 대한 수요 증가로 인해 발생합니다. 주요 촉진요인으로는 전 세계 감염병 발병률 증가, 백신 효능 향상에 대한 수요 증가, 백신 개발에 대한 정부 및 민간 부문의 지속적인 투자를 들 수 있습니다. 백신 보조제 시장 개척의 기회는 더 나은 안전성 프로파일을 가진 차세대 보조제 개발과 암 백신을 포함한 맞춤형 의료에서 보조제 사용의 확대에 있습니다. 시장 동향으로는 리포솜 기반 및 사포닌 기반 보조제 등 보다 진보된 보조제 기술로의 전환과 새로운 건강 위협에 대응하기 위한 백신 연구의 확대가 있습니다. 전반적으로 이 시장은 기술 혁신, 전략적 제휴, 세계 의료 수요 증가에 힘입어 꾸준히 성장할 수 있는 여건을 갖추고 있습니다.

백신 보조제 시장 : 분석 개요

제품 유형별로 보면 명반 분야는 백신에 오랜 기간 사용되어 안전성이 입증되어 가장 큰 시장 점유율을 차지하고 있습니다. 그러나 보조제 에멀전은 감염병 및 전염병 백신에서 면역 반응 강화에 힘입어 가장 빠르게 성장하고 있는 분야입니다.

투여 경로별로는 독감, COVID-19 등 다양한 감염병 백신에 널리 사용되는 근육 내 투여 경로가 시장을 주도하고 있습니다. 피하 투여는 특히 치료용 백신 및 면역요법에 적용될 때 가장 높은 성장세를 보이고 있습니다.

질병 유형별로는 인플루엔자, 간염, COVID-19와 같은 질병에 대한 백신 접종 프로그램이 진행됨에 따라 감염성 질환 분야가 백신 보조제 시장의 매출 점유율을 주도하고 있습니다. 암 분야는 면역요법 백신과 맞춤의료의 발전에 힘입어 가장 높은 성장세를 보이고 있습니다.

보조제를 첨가한 백신이 전 세계 공중보건 활동에서 널리 사용됨에 따라, 용도별로는 상업용 응용 분야가 백신 보조제 시장 점유율을 주도하고 있습니다. 연구용 분야는 백신 개발 및 임상시험, 특히 암 백신과 치료용 백신에 대한 투자 증가에 힘입어 가장 빠르게 성장하고 있습니다.

북미는 강력한 의료 인프라와 백신 연구 투자로 인해 가장 큰 시장 점유율을 차지하고 있습니다. 아시아태평양은 의료 수요 확대, 인구 증가, 백신 채택 증가로 인해 가장 높은 성장세를 보이고 있습니다.

시장 현황
백신 보조제 시장 역학
- 성장 촉진요인과 기회
  - 첨단 보조제 기술에 대한 주목 상승
  - 팬데믹 대책에서 보조제의 역할 확대
  - 개별화 백신 보조제 전략 확대
- 성장 억제요인과 과제
  - 규제상 과제
PESTLE 분석
백신 보조제 시장 동향
밸류체인 분석
COVID-19의 영향 분석

제5장 세계의 백신 보조제 시장 : 제품 종류별

주요 조사 결과
소개
미립자 보조제
보조제 에멀전
병원체 성분
명반
기타

제6장 세계의 백신 보조제 시장 : 투여 경로별

주요 조사 결과
소개
근육내 투여
피하 투여
기타

제7장 세계의 백신 보조제 시장 : 질환 종류별

주요 조사 결과
소개
감염증
암
기타

제8장 세계의 백신 보조제 시장 : 용도별

주요 조사 결과
소개
연구 용도
상업 용도

제9장 세계의 백신 보조제 시장 : 지역별

주요 조사 결과
소개
- 백신 보조제 시장 평가 : 지역별(2020-2034년)
북미
- 북미 : 제품 종류별(2020-2034년)
- 북미 : 투여 경로별(2020-2034년)
- 북미 : 용도별(2020-2034년)
- 북미 : 질환 종류별(2020-2034년)
- 미국
- 캐나다
유럽
- 유럽 : 제품 종류별(2020-2034년)
- 유럽 : 투여 경로별(2020-2034년)
- 유럽 : 용도별(2020-2034년)
- 유럽 : 질환 종류별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
아시아태평양
- 아시아태평양 : 제품 종류별(2020-2034년)
- 아시아태평양 : 투여 경로별(2020-2034년)
- 아시아태평양 : 용도별(2020-2034년)
- 아시아태평양 : 질환 종류별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
중동 및 아프리카
- 중동 및 아프리카 : 제품 종류별(2020-2034년)
- 중동 및 아프리카 : 투여 경로별(2020-2034년)
- 중동 및 아프리카 : 용도별(2020-2034년)
- 중동 및 아프리카 : 질환 종류별(2020-2034년)
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
라틴아메리카
- 라틴아메리카 : 제품 종류별(2020-2034년)
- 라틴아메리카 : 투여 경로별(2020-2034년)
- 라틴아메리카 : 용도별(2020-2034년)
- 라틴아메리카 : 질환 종류별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카

제10장 경쟁 구도

사업 확대·기업 인수 분석
- 사업 확대
- 기업 인수
제휴/협업/합의/공개

제11장 기업 개요

GlaxoSmithKline(GSK)
Novavax
Merck & Co.
Sanofi
CSL Limited
Adjuvance Technologies
SEPPIC
Croda International
Vaxine Pty Ltd
Brenntag Biosector
Vaccitech(University of Oxford spin-off)
Emergent BioSolutions
Avanti Polar Lipids
Daiichi Sankyo
ImmunoScience

ksm 25.03.10

The global vaccine adjuvants market size is expected to reach USD 6,035.04 million by 2034, according to a new study by Polaris Market Research. The report "Vaccine Adjuvants Market Size, Share, Trends, Industry Analysis Report: By Product Type (Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components, Alum, and Others), Route of Administration, Disease Type, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The vaccine adjuvants market involves substances added to vaccines to enhance immune responses. These adjuvants improve the efficacy of vaccines, particularly for challenging diseases. Growing demand for vaccines, advancements in adjuvant technologies, and increased awareness of immunization are driving market growth. Key players focus on developing new adjuvants with improved safety and effectiveness. The market is fueled by rising vaccination programs and the need for vaccines against emerging diseases, including COVID-19.

The vaccine adjuvants market growth is driven by the increasing demand for effective vaccines, particularly for infectious diseases and cancer immunotherapy. Key drivers include the rising incidence of infectious diseases across the world, increasing need for enhanced vaccine efficacy, and continued government and private sector investments in vaccine development. Vaccine adjuvants market opportunities lie in the development of next-generation adjuvants with better safety profiles and the growing use of adjuvants in personalized medicine, including cancer vaccines. Market trends include a shift toward more advanced adjuvant technologies, such as liposome-based and saponin-based adjuvants, and the expansion of vaccine research in response to emerging health threats. Overall, the market is poised for steady growth, supported by innovation, strategic collaborations, and increasing healthcare needs worldwide.

Vaccine Adjuvants Market Report Highlights

Based on product type, the alum segment holds the largest market share due to its long-standing use in vaccines and proven safety. However, adjuvant emulsions are the fastest-growing segment, driven by their enhanced immune response in vaccines for infectious diseases and pandemics.

By route of administration, the intramuscular route segment dominates the market due to its widespread use in vaccines for various infectious diseases, such as influenza and COVID-19. The subcutaneous route is registering the highest growth, particularly in therapeutic vaccines and immunotherapy applications.

In terms of disease type, the infectious diseases segment dominates the vaccine adjuvants market revenue share, driven by ongoing vaccination programs for diseases such as influenza, hepatitis, and COVID-19. The cancer segment is experiencing the highest growth, fueled by advancements in immunotherapy vaccines and personalized medicine.

The commercial application segment, by application, leads the vaccine adjuvants market share owing to the widespread use of adjuvanted vaccines in public health initiatives globally. The research application segment is growing the fastest, supported by increased investments in vaccine development and clinical trials, especially in cancer and therapeutic vaccines.

North America holds the largest market share due to its strong healthcare infrastructure and substantial vaccine research investments. Asia Pacific is registering the highest growth, driven by expanding healthcare needs, large populations, and increasing vaccine adoption.

Polaris Market Research has segmented the vaccine adjuvants market report on the basis of product type, route of administration, disease type, application, and region:

By Product Type Outlook (Revenue - USD Million, 2020-2034)

Particulate Adjuvants
Adjuvant Emulsions
Pathogen Components
Alum
Others

By Route of Administration Outlook (Revenue - USD Million, 2020-2034)

Intramuscular Route
Subcutaneous Route
Others

By Disease Type Outlook (Revenue - USD Million, 2020-2034)

Infectious Diseases
Cancer
Others

By Application Outlook (Revenue - USD Million, 2020-2034)

Research Application
Commercial Application

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. Global Vaccine Adjuvants Market Insights

4.1. Vaccine Adjuvants Market - Market Snapshot
4.2. Vaccine Adjuvants Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Focus on Advanced Adjuvant Technologies
  - 4.2.1.2. Growing Role of Adjuvants in Pandemic Preparedness
  - 4.2.1.3. Expansion of Personalized Vaccine Adjuvant Strategies
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Regulatory Challenges
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Vaccine Adjuvants Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Vaccine Adjuvants Market, by Product Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
5.3. Particulate Adjuvants
- 5.3.1. Global Vaccine Adjuvants Market, by Particulate Adjuvants, by Region, 2020-2034 (USD Million)
5.4. Adjuvant Emulsions
- 5.4.1. Global Vaccine Adjuvants Market, by Adjuvant Emulsions, by Region, 2020-2034 (USD Million)
5.5. Pathogen Components
- 5.5.1. Global Vaccine Adjuvants Market, by Pathogen Components, by Region, 2020-2034 (USD Million)
5.6. Alum
- 5.6.1. Global Vaccine Adjuvants Market, by Alum, by Region, 2020-2034 (USD Million)
5.7. Others
- 5.7.1. Global Vaccine Adjuvants Market, by Others, by Region, 2020-2034 (USD Million)

6. Global Vaccine Adjuvants Market, by Route of Administration

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
6.3. Intramuscular Route
- 6.3.1. Global Vaccine Adjuvants Market, by Intramuscular Route, by Region, 2020-2034 (USD Million)
6.4. Subcutaneous Route
- 6.4.1. Global Vaccine Adjuvants Market, by Subcutaneous Route, by Region, 2020-2034 (USD Million)
6.5. Others
- 6.5.1. Global Vaccine Adjuvants Market, by Others, by Region, 2020-2034 (USD Million)

7. Global Vaccine Adjuvants Market, by Disease Type

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
7.3. Infectious Diseases
- 7.3.1. Global Vaccine Adjuvants Market, by Infectious Diseases, by Region, 2020-2034 (USD Million)
7.4. Cancer
- 7.4.1. Global Vaccine Adjuvants Market, by Cancer, by Region, 2020-2034 (USD Million)
7.5. Others
- 7.5.1. Global Vaccine Adjuvants Market, by Others, by Region, 2020-2034 (USD Million)

8. Global Vaccine Adjuvants Market, by Application

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
8.3. Research Application
- 8.3.1. Global Vaccine Adjuvants Market, by Research Application, by Region, 2020-2034 (USD Million)
8.4. Commercial Application
- 8.4.1. Global Vaccine Adjuvants Market, by Commercial Application, by Region, 2020-2034 (USD Million)

9. Global Vaccine Adjuvants Market, by Geography

9.1. Key Findings
9.2. Introduction
- 9.2.1. Vaccine Adjuvants Market Assessment, By Geography, 2020-2034 (USD Million)
9.3. Vaccine Adjuvants Market - North America
- 9.3.1. North America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
- 9.3.2. North America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
- 9.3.3. North America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
- 9.3.4. North America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.3.5. Vaccine Adjuvants Market - US
  - 9.3.5.1. US: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.3.5.2. US: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.3.5.3. US: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.3.5.4. US: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.3.6. Vaccine Adjuvants Market - Canada
  - 9.3.6.1. Canada: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.3.6.2. Canada: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.3.6.3. Canada: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.3.6.4. Canada: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
9.4. Vaccine Adjuvants Market - Europe
- 9.4.1. Europe: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
- 9.4.2. Europe: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
- 9.4.3. Europe: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
- 9.4.4. Europe: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.5. Vaccine Adjuvants Market - UK
  - 9.4.5.1. UK: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.5.2. UK: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.5.3. UK: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.5.4. UK: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.6. Vaccine Adjuvants Market - France
  - 9.4.6.1. France: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.6.2. France: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.6.3. France: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.6.4. France: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.7. Vaccine Adjuvants Market - Germany
  - 9.4.7.1. Germany: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.7.2. Germany: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.7.3. Germany: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.7.4. Germany: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.8. Vaccine Adjuvants Market - Italy
  - 9.4.8.1. Italy: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.8.2. Italy: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.8.3. Italy: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.8.4. Italy: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.9. Vaccine Adjuvants Market - Spain
  - 9.4.9.1. Spain: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.9.2. Spain: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.9.3. Spain: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.9.4. Spain: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.10. Vaccine Adjuvants Market - Netherlands
  - 9.4.10.1. Netherlands: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.10.2. Netherlands: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.10.3. Netherlands: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.10.4. Netherlands: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.11. Vaccine Adjuvants Market - Russia
  - 9.4.11.1. Russia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.11.2. Russia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.11.3. Russia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.11.4. Russia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.4.12. Vaccine Adjuvants Market - Rest of Europe
  - 9.4.12.1. Rest of Europe: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.4.12.2. Rest of Europe: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.4.12.3. Rest of Europe: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.4.12.4. Rest of Europe: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
9.5. Vaccine Adjuvants Market - Asia Pacific
- 9.5.1. Asia Pacific: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
- 9.5.2. Asia Pacific: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
- 9.5.3. Asia Pacific: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
- 9.5.4. Asia Pacific: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.5. Vaccine Adjuvants Market - China
  - 9.5.5.1. China: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.5.2. China: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.5.3. China: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.5.4. China: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.6. Vaccine Adjuvants Market - India
  - 9.5.6.1. India: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.6.2. India: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.6.3. India: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.6.4. India: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.7. Vaccine Adjuvants Market - Malaysia
  - 9.5.7.1. Malaysia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.7.2. Malaysia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.7.3. Malaysia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.7.4. Malaysia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.8. Vaccine Adjuvants Market - Japan
  - 9.5.8.1. Japan: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.8.2. Japan: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.8.3. Japan: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.8.4. Japan: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.9. Vaccine Adjuvants Market - Indonesia
  - 9.5.9.1. Indonesia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.9.2. Indonesia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.9.3. Indonesia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.9.4. Indonesia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.10. Vaccine Adjuvants Market - South Korea
  - 9.5.10.1. South Korea: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.10.2. South Korea: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.10.3. South Korea: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.10.4. South Korea: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.11. Vaccine Adjuvants Market - Australia
  - 9.5.11.1. Australia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.11.2. Australia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.11.3. Australia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.11.4. Australia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.5.12. Vaccine Adjuvants Market - Rest of Asia Pacific
  - 9.5.12.1. Rest of Asia Pacific: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.5.12.2. Rest of Asia Pacific: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.5.12.3. Rest of Asia Pacific: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.5.12.4. Rest of Asia Pacific: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
9.6. Vaccine Adjuvants Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
- 9.6.2. Middle East & Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
- 9.6.3. Middle East & Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
- 9.6.4. Middle East & Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.6.5. Vaccine Adjuvants Market - Saudi Arabia
  - 9.6.5.1. Saudi Arabia: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.6.5.2. Saudi Arabia: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.6.5.3. Saudi Arabia: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.6.5.4. Saudi Arabia: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.6.6. Vaccine Adjuvants Market - UAE
  - 9.6.6.1. UAE: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.6.6.2. UAE: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.6.6.3. UAE: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.6.6.4. UAE: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.6.7. Vaccine Adjuvants Market - Israel
  - 9.6.7.1. Israel: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.6.7.2. Israel: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.6.7.3. Israel: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.6.7.4. Israel: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.6.8. Vaccine Adjuvants Market - South Africa
  - 9.6.8.1. South Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.6.8.2. South Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.6.8.3. South Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.6.8.4. South Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.6.9. Vaccine Adjuvants Market - Rest of Middle East & Africa
  - 9.6.9.1. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.6.9.2. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.6.9.3. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.6.9.4. Rest of Middle East & Africa: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
9.7. Vaccine Adjuvants Market - Latin America
- 9.7.1. Latin America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
- 9.7.2. Latin America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
- 9.7.3. Latin America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
- 9.7.4. Latin America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.7.5. Vaccine Adjuvants Market - Mexico
  - 9.7.5.1. Mexico: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.7.5.2. Mexico: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.7.5.3. Mexico: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.7.5.4. Mexico: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.7.6. Vaccine Adjuvants Market - Brazil
  - 9.7.6.1. Brazil: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.7.6.2. Brazil: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.7.6.3. Brazil: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.7.6.4. Brazil: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.7.7. Vaccine Adjuvants Market - Argentina
  - 9.7.7.1. Argentina: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.7.7.2. Argentina: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.7.7.3. Argentina: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.7.7.4. Argentina: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)
- 9.7.8. Vaccine Adjuvants Market - Rest of Latin America
  - 9.7.8.1. Rest of Latin America: Vaccine Adjuvants Market, by Product Type, 2020-2034 (USD Million)
  - 9.7.8.2. Rest of Latin America: Vaccine Adjuvants Market, by Route of Administration, 2020-2034 (USD Million)
  - 9.7.8.3. Rest of Latin America: Vaccine Adjuvants Market, by Application, 2020-2034 (USD Million)
  - 9.7.8.4. Rest of Latin America: Vaccine Adjuvants Market, by Disease Type, 2020-2034 (USD Million)

10. Competitive Landscape

10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

11.1. GlaxoSmithKline (GSK)
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
11.2. Novavax
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
11.3. Merck & Co.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
11.4. Sanofi
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
11.5. CSL Limited
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
11.6. Adjuvance Technologies
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
11.7. SEPPIC
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
11.8. Croda International
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
11.9. Vaxine Pty Ltd
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
11.10. Brenntag Biosector
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
11.11. Vaccitech (University of Oxford spin-off)
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
11.12. Emergent BioSolutions
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
11.13. Avanti Polar Lipids
- 11.13.1. Company Overview
- 11.13.2. Financial Performance
- 11.13.3. Product Benchmarking
- 11.13.4. Recent Development
11.14. Daiichi Sankyo
- 11.14.1. Company Overview
- 11.14.2. Financial Performance
- 11.14.3. Product Benchmarking
- 11.14.4. Recent Development
11.15. ImmunoScience
- 11.15.1. Company Overview
- 11.15.2. Financial Performance
- 11.15.3. Product Benchmarking
- 11.15.4. Recent Development